KR102510297B1 - A composition for the prevention or treatment of depression, stress or memory malfunctions containing Erythronium japonicum extract - Google Patents

Abstract

The present invention relates to a composition for improving, preventing or treating depressive symptoms, stress or cognitive dysfunction, and by containing Erythronium japonicum extract as an active ingredient, depressive symptoms, stress or cognitive dysfunction can be improved, prevented or treated. there is. In addition, since it is non-toxic, it can be ingested in the form of food.

Description

Composition for improving, preventing, or treating depressive symptoms, stress, or cognitive dysfunction, containing an extract of A.

The present invention relates to a composition capable of improving, preventing or treating depressive symptoms, stress or cognitive dysfunction by containing an extract of Erythronium japonicum as an active ingredient.

As society develops and diversifies rapidly, modern people are required to play various roles. Accordingly, the number of people complaining of mental disorders such as depression, anxiety disorders, or sleep disorders caused by various stresses is increasing. According to the 2006 Epidemiological Survey of Mental Disorders conducted by the Ministry of Health and Welfare for adults aged 18 to 64 years old, the '1-year prevalence rate of mental illness' was 17.1%.

In addition, the 'lifetime prevalence of mental illness', which is the percentage of the population who has experienced one or more mental illnesses during their lifetime, was 30%, one in three adults (as of 2006). In addition, due to causes such as excessive academic fever, there is a trend of increasing adolescent mental illness.

Stress refers to a state of physical or psychological pressure, which is caused by factors that are prevalent in daily life and contributes to the occurrence of almost all psychiatric and medical diseases. However, if stress is left unattended without being able to cope with it, psychological reactions such as depression, anxiety, fatigue, anger, mood changes, and physiological reactions such as a decrease in α-waves among brain waves and an increase in blood pressure and pulse rate are caused. If the reaction is repeated over and over again, diseases such as depression, anxiety, and sleep disorders appear, cause personal, family and social losses, and reduce the quality of life of individuals.

Among diseases caused by stress, depression refers to a psychological state of depressed mood characterized by feelings of sadness, hopelessness, and frustration. In other words, it means a state that has developed from "depressive", which is a normal emotion, dysthymic disorder to major depressive disorder.

The main symptoms of depression include changes in appetite, weight or sleep patterns, psychomotor agitation or retardation, decreased ability to think, concentrate or make decisions, lack of energy and fatigue, feelings of worthlessness, guilt or a major depressive episode, a period in which the usual depressed mood or loss of interest or pleasure in most activities, combined with guilt, frequent death or suicidal thoughts, or some of the plans or attempts to commit suicide to be characterized

Treatments for depressive symptoms currently used clinically are generally developed and tested through animal models of depressive symptoms. It is understood that all therapeutic agents for depressive symptoms have pharmacological actions that enhance drug action at synapses by inhibiting the degradation and reuptake of monoamines such as dopamine, serotonin, and norepinephrine, which are neurotransmitters between brain neurons. However, the drug has a large difference in efficacy depending on the patient, so it is necessary to develop a new antidepressant that supplements or replaces these problems.

According to the statistics of treatment for depressive symptoms recently announced by the National Health Insurance Service, the number of depressed patients increased by 12.4% in 2011 compared to 2007. 1, and the number of people who committed suicide due to this cause is on the rise, with 4,132 (28.1%) in 2009 and 4,357 (29.5%) in 2010. In addition to depression, the number of Attention Deficit/Hyperactivity Disorder (ADHD) patients also increased by 9,000 over the past 5 years, from 48,000 in 2007 to 57,000 in 2012, showing an average annual increase of 4.4%. .

Therefore, extracts from natural products that can rapidly improve, prevent or treat depressive symptoms, stress or cognitive dysfunction, and are safe and have no side effects are required.

Korean Registered Patent No. 1692032 Republic of Korea Patent Publication No. 2016-0022190

An object of the present invention is to provide a food composition capable of improving or preventing depressive symptoms, stress or cognitive dysfunction by containing an extract of Erythronium japonicum as an active ingredient.

In addition, another object of the present invention is to provide a pharmaceutical composition capable of preventing or treating depressive symptoms, stress or cognitive dysfunction by containing an extract of Erythronium japonicum as an active ingredient.

In addition, another object of the present invention is to provide a feed composition capable of preventing or improving depressive symptoms, stress or cognitive dysfunction by containing an extract of Erythronium japonicum as an active ingredient.

In addition, another object of the present invention is to provide a pharmaceutical composition for animals that can prevent or treat depressive symptoms, stress or cognitive dysfunction by containing an extract of Erythronium japonicum as an active ingredient.

Food composition capable of improving or preventing depressive symptoms, stress or cognitive dysfunction of the present invention for achieving the above object may contain an extract of Erythronium japonicum as an active ingredient.

The extract may be an extract of a leaf of a leaf of a leaf.

The extract may be extracted with water, lower alcohol having 1 to 4 carbon atoms, ethylene glycol, ethyl ether, or a mixed solvent thereof.

The lower alcohol having 1 to 4 carbon atoms may be 20 to 80% methanol, ethanol, butanol or propanol.

The extract may be extracted with 20 to 80% ethanol aqueous solution.

The extraction temperature is 60 to 100 ℃, the extraction time may be 5 to 15 hours.

Immobility time during forced swimming after ingestion of the composition may be 130 to 150 seconds.

In addition, the pharmaceutical composition capable of preventing or treating depressive symptoms, stress or cognitive dysfunction of the present invention for achieving the above other object may contain an extract of Erythronium japonicum as an active ingredient.

The extract may be an extract of a leaf of a leaf of a leaf.

Immobility time during forced swimming after ingestion of the composition may be 130 to 150 seconds.

In addition, the feed composition capable of preventing or improving depressive symptoms, stress or cognitive dysfunction of the present invention for achieving the above another object may contain an extract of Erythronium japonicum as an active ingredient.

In addition, the pharmaceutical composition for animals capable of preventing or treating depressive symptoms, stress or cognitive dysfunction of the present invention for achieving the above another object may contain an extract of Erythronium japonicum as an active ingredient.

A composition for improving, preventing or treating depressive symptoms, stress or cognitive dysfunction containing the extract of Erythronium japonicum of the present invention as an active ingredient is non-toxic and improves, prevents or treats depressive symptoms, stress or cognitive dysfunction. It is effective in the preparation of competitive food compositions and pharmaceutical compositions because of its excellent therapeutic effect.

In addition, since the extract of Erythronium japonicum of the present invention is non-toxic, it can be used as a feed additive composition.

Figure 1 is a graph showing the results of the manual avoidance experiment of the normal group, control group 1, control group 2 and the extract prepared according to Example 1 of the present invention.
Figure 2 is a diagram showing the behavioral patterns of (A) normal group, (B) control group 1, (C) control group 2, and (D) Example 1 (300) group of the present invention.
3 shows (A) the total distance traveled by the normal group, control group 1, control group 2, Example 1 (100) group and Example 1 (300) group, (B) normal group, control group 1, control group 2, Example Time for the 1 (100) group and Example 1 (300) group to stay in the center, and (C) the normal group, the control group 1, the control group 2, the Example 1 (100) group, and the Example 1 (300) group prefer the corner This is a graph showing an hour.

The present invention relates to a composition capable of improving, preventing or treating depressive symptoms, stress or cognitive dysfunction by containing an extract of Erythronium japonicum as an active ingredient.

Hereinafter, the present invention will be described in detail.

The composition for improving, preventing or treating depressive symptoms, stress or cognitive dysfunction of the present invention contains an extract of Erythronium japonicum as an active ingredient.

The Erythronium japonicum is usually used as a rhizome, and in the private sector, it is consumed as a cardiac agent, an antipyretic, an antidote, a diuretic, and an inflammatory drug, and the leaves are also used as a diuretic and anti-inflammatory.

In the present invention, as using the leaf of the leaf, in the case of using the rhizome of the leaf of the leaf, the improvement, prevention or treatment effect of depressive symptoms, stress or cognitive dysfunction may be reduced.

After mixing with the extraction solvent at a weight ratio of 1: 5 to 25, preferably 1: 8 to 15, extracting at 60 to 100 ° C. for 5 to 15 hours, preferably 6 to 10 hours, and then at 50 to 60 ° C. Concentration under reduced pressure is performed to prepare the extract. In the case where the weight ratio of the Japanese calla lily and the extraction solvent is out of the above range, a small amount of the active ingredient of the Italian species of this plant may be extracted in the extract.

If the extraction temperature and extraction time are less than the lower limit, the active ingredient of the plant may be extracted in a small amount, and the effect of improving, preventing or treating depressive symptoms, stress or cognitive dysfunction may be reduced.

The extraction solvent for extracting each extract is water, lower alcohol having 1 to 4 carbon atoms, ethylene glycol, ethyl ether, or a mixture thereof. Examples of the lower alcohol include 20 to 80% methanol, ethanol, butanol or propanol.

The extraction solvent is not particularly limited, but the extract extracted with 20 to 80% aqueous ethanol solution preferably acts to improve, prevent or treat depressive symptoms, stress or cognitive dysfunction.

It was confirmed that the ingestion of the extract of the plant extract of the present invention has a short immobility time of 130 to 150 seconds during forced swimming, so that it preferably acts to improve, prevent, or treat depressive symptoms.

The term 'extract' used in the present invention includes extracts obtained by extracting components contained in the plant extract using the solvent, fractions fractionated therefrom, concentrates obtained by additionally concentrating these extracts or fractions, and purified or separated purified products thereof. , It is used in the sense of including a dried product of the extract, fraction, concentrate, or purified product, or a powder obtained by pulverizing the same.

For the preparation of the purified product, a variety of additionally carried out, such as passing through an ultrafiltration membrane having a molecular weight cut-off value, or separation by various chromatography (made for separation according to size, charge, hydrophobicity or affinity). A purification method may be added.

The present invention relates to a food composition for preventing or improving depressive symptoms, stress, or cognitive dysfunction, comprising an extract of Asparagus japonica as an active ingredient.

The 'food composition' includes food ingredients usable as food described in the food standards and specifications ('Food Code') commonly used in food manufacturing, and food additives described in the Food Additives Code, in addition to the extract of Aspergillus japonica as an active ingredient. .

It does not need to be particularly limited, but includes, for example, proteins, carbohydrates, fats, nutrients, seasonings and flavoring agents. The carbohydrates include monosaccharides such as glucose, fructose, and the like; disaccharides such as maltose, sugar, lactose and the like; oligosaccharides or polysaccharides such as dextrin, starch syrup, cyclodextrin and the like; Sugar alcohols such as xylitol, sorbitol, erythritol and the like can be used. As the flavoring agent, natural flavoring agents (thaumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) may be used.

When a food composition is prepared using the extract of the Italian cabbage extract as an active ingredient, the extract of the Italian cabbage extract does not need to be particularly limited as long as it can prevent or treat depressive symptoms, stress or cognitive dysfunction, but, for example, 0.1 to 99% by weight, 0.5 to 90% by weight 95% by weight, 1 to 90% by weight, 2 to 80% by weight, 3 to 70% by weight, 4 to 60% by weight, may be included in 5 to 50% by weight.

In the food composition, the active ingredient, the extract of the japonica extract, varies depending on the condition, weight, presence or absence or degree and period of disease of the eater, but may be appropriately selected by a person skilled in the art. For example, it may be 1 to 5,000 mg, preferably 5 to 2,000 mg, more preferably 10 to 1,000 mg, still more preferably 20 to 800 mg, and most preferably 50 to 500 mg based on the daily dose. There is, and the number of administrations need not be particularly limited, but can be adjusted by a person skilled in the art within the range of three times a day to once a week. In the case of long-term intake for the purpose of health and hygiene or health control, it may be less than the above range.

The food composition does not need to be particularly limited, but may be, for example, a powder, granule, tablet, capsule, pill, extract, jelly formulation, tea bag formulation or beverage formulation.

In addition, in order to give the functionality of preventing or improving depressive symptoms, stress, or cognitive dysfunction to general foods, the extract of the Asian Japanese cabbage can be added, and foods that can be added do not need to be particularly limited, but, for example, Article 7 of the Food Sanitation Act Confectionery, bread or rice cakes, processed cocoa products or chocolates, processed meat or egg products, processed fish meat products, tofu or jelly, noodles, teas, coffee, beverages, special It can be added to foods for use, sauces, seasoned foods, dressings, kimchi, salted fish, pickled foods, stewed foods, alcoholic beverages, raisins, and other foods. In addition, it can be added to dairy products, processed meat products, packaged meat, and egg products exemplified in the processing standards and ingredient specifications of livestock products ('Livestock Codex') according to Article 4 of the Livestock Products Sanitation Control Act.

On the other hand, the food composition containing the extract of Asparagus japonica as an active ingredient can be used alone as "health functional food for preventing or improving depressive symptoms, stress or cognitive dysfunction".

The 'health functional food' refers to food manufactured (including processing) according to legal standards using raw materials or ingredients having functional properties useful for the human body (Article 3, Subparagraph 1 of the Health Functional Food Act). The term 'health functional food' may differ in terminology or scope from country to country, but 'Dietary Supplement' in the US, 'Food Supplement' in Europe, 'Health Functional Food' or 'Health Functional Food' in Japan. It may correspond to 'Food for Special Health Use (FoSHU)' or 'Health Food' in China.

The food composition or health functional food may additionally contain food additives, and the suitability as a food additive is determined according to the standards and standards for the item in accordance with the general rules and general test methods of the 'Food Additive Code' unless otherwise specified. follow

In addition, in the health functional food, as a raw material notified as a 'functional raw material' or individually recognized raw material used in "health functional food for preventing or improving depressive symptoms, stress or cognitive dysfunction" together with the extract of Asian hair, creatine, Health functional food for preventing or improving depressive symptoms, stress, or cognitive dysfunction can be manufactured by combining health functional food materials related to exercise ability such as euphorbia extract powder and maca gelatinized powder.

The present invention relates to a feed composition for preventing or improving depressive symptoms, stress or cognitive dysfunction, comprising an extract of A.

The 'feed composition' can use food ingredients and food additives described in the Food Additives Code that can be used as food described in the standards and specifications of food ('Food Code'), in addition to the extract of Japanese hairy plant as an active ingredient, and can be used as food Even if they are not raw materials or food additives, raw materials that fall under the scope of single feed in Attached Table 1 of 'Standards and Specifications for Feed, etc.' and raw materials that fall under the scope of supplementary feed under Attached Table 2 can be used.

The 'feed composition' may be an extractant in supplementary feed according to 'standards and specifications for feed, etc.', and may be a formulated feed containing the supplementary feed.

In the case of preparing a feed composition using the extract of the Italian plant extract as an active ingredient, the content of the extract of the Italian plant extract is not particularly limited as long as it shows the prevention or improvement of depressive symptoms, stress or cognitive dysfunction, but, for example, 0.1 to 99% by weight, 0.5 to 90% by weight 95% by weight, 1 to 90% by weight, 2 to 80% by weight, 3 to 70% by weight, 4 to 60% by weight, may be included in 5 to 50% by weight.

In the feed composition, the active ingredient, the extract, of the animal, varies depending on the condition, body weight, presence or absence or degree and duration of the disease, but may be appropriately selected by a person skilled in the art. For example, 1 to 5,000 mg, preferably 5 to 2,000 mg, more preferably 10 to 1,000 mg, even more preferably 20 to 800 mg, most preferably 50 to 500 mg, based on the daily dose The number of administrations may be adjusted within the range of three times a day to once a week by a person skilled in the art, although there is no need to specifically limit the number of administrations. In the case of long-term intake for the purpose of health and hygiene or health control, it may be less than the above range.

The present invention relates to a pharmaceutical composition for the prevention or treatment of depressive symptoms, stress or cognitive dysfunction, comprising an extract of A.

In addition, the present invention relates to a pharmaceutical composition for animals for preventing or treating depressive symptoms, stress, or cognitive dysfunction, comprising an extract of Japanese violet chinensis as an active ingredient.

In addition, the present invention provides a method for treating depressive symptoms, stress or cognitive dysfunction by administering the composition to humans or non-human animals.

In addition, the present invention provides a new use of the extract of the extract for the prevention or treatment of depressive symptoms, stress or cognitive dysfunction, or for the preparation of veterinary medicine.

The 'pharmaceutical composition', 'medicine', 'veterinary pharmaceutical composition' or 'veterinary medicine' may further include appropriate carriers, excipients and diluents commonly used in the manufacture of pharmaceutical compositions, etc. can

The 'carrier' is a compound that facilitates the addition of the compound into cells or tissues. The 'diluent' is a compound diluted in water that not only stabilizes the biologically active form of the subject compound, but also dissolves the compound.

The carrier, excipient, and diluent are not particularly limited, but, for example, lactose, glucose, sugar, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil.

The amount of the pharmaceutical composition, drug, veterinary pharmaceutical composition, or veterinary drug used may vary depending on the age, sex, and weight of the patient or animal to be treated, and above all, the condition of the subject to be treated, a specific category of disease to be treated, or It will depend on the type, route of administration, and nature of the therapeutic used.

The pharmaceutical composition, drug, veterinary pharmaceutical composition or veterinary drug is appropriately selected according to the absorption rate of the active ingredient in the body, the rate of excretion, the age and weight, sex and condition of the patient or animal to be treated, the severity of the disease to be treated, etc. , It is generally preferred to administer 0.1 to 1,000 mg/kg, preferably 1 to 500 mg/kg, more preferably 5 to 250 mg/kg, and most preferably 10 to 100 mg/kg per day. The unit dosage form formulation thus formulated can be administered several times at regular time intervals as needed.

The pharmaceutical composition, medicament, veterinary pharmaceutical composition, or veterinary medicament may be administered individually as a prophylactic or therapeutic agent, or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents.

The pharmaceutical composition, drug, veterinary pharmaceutical composition, or veterinary drug may be formulated into oral dosage forms such as powders, granules, tablets, capsules, troches, suspensions, emulsions, syrups, aerosols, etc. according to conventional methods and used. there is. When formulated, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.

Solid preparations for oral administration include tablets, pills, powders, granules, capsules, troches, etc., and these solid preparations contain at least one excipient such as starch, calcium carbonate, sugar or lactose, and gelatin in the compound. It can be prepared by mixing etc. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral use include suspensions, solutions for oral use, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. .

The method for treating depressive symptoms, stress or cognitive dysfunction is to administer the composition to humans, or non-human animals, particularly mammals, for example, to a subject having depressive symptoms, stress or cognitive dysfunction. to administer the composition.

Whether or not the subject to be treated with depressive symptoms, stress, or cognitive dysfunction may be a case of having depressive symptoms, stress, or cognitive dysfunction.

The dosage, administration method and number of administrations for the treatment may refer to the dosage, administration method and number of administrations of the pharmaceutical composition, medicine, veterinary pharmaceutical composition or veterinary medicine.

Hereinafter, preferred embodiments are presented to aid understanding of the present invention, but the following examples are merely illustrative of the present invention, and various changes and modifications are possible within the scope and spirit of the present invention. It is obvious to those skilled in the art, It goes without saying that these variations and modifications fall within the scope of the appended claims.

Example 1. Ethanol extract from the leaves of Japanese violets

Dried plants of Italian plants and 70% aqueous ethanol solution were mixed at a weight ratio of 1:10 and extracted at 80° C. for 6 hours to obtain a leaf extract of plants of plants of this species.

Example 2. Ethanol extract from the rhizomes of Japanese violets

It was carried out in the same manner as in Example 1, but using the dried Italian cattail rhizome instead of the plant leaf leaf to obtain an extract of the plant stem rhizome.

<Test Example>

prepared in the examples After filtering the extract, the filtrate was concentrated under reduced pressure at 60 °C or less.

animal testing

250-300 g ICR mice (5 weeks old, Coretech, Korea, male) were used in the experiment. Raised in an acrylic cage (45 X 60 X 25 cm), sufficient feed and water were supplied, and 12 hours of day and night were controlled with appropriate artificial lighting (day from 8:00 am). And a constant temperature (20 ~ 24 ℃) and humidity (45 ~ 65%) was maintained. The sleep cycle was maintained for a week to adapt to the changed environment, and abnormal behavior was checked.

Animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of the Korea Food Research Institute.

Experimental animals were selected only healthy animals with constant body weight change, and the normal group administered with physiological saline, LPS (Lipopolysaccharide) administered control group, and LPS (Lipopolysaccharide) administered extract of Examples 1 and 2 by random batch method were divided into oral administration sample administration groups, and 5 animals were used in each experimental group.

At this time, LPS (Lipopolysaccharide) was administered by injection at 1 mg/kg once a day at a constant time for 3 days, and the extracts of Examples 1 and 2 were dissolved in saline at the following concentrations (100, 300 mg/kg) to obtain 100 ul orally After administration, behavioral experiments were conducted 60 minutes later.

It is an 'LPS-induced depressive-like behavior model' that appears by the induction of neuroinflammation according to the administration of the LPS (Lipopolysaccharide). LPS is a liposaccharide, an endotoxin, and when a certain amount is intraperitoneally administered to ICR mice, abnormal activation of microglia in charge of immune function in the brain occurs, resulting in increased inflammatory response and production of neurotransmitters such as serotonin. This leads to symptoms similar to those of depression.

-7 groups of mice-

Normal group: 5 animals administered with physiological saline for 3 days_1 mg/kg/day

Control group 1: LPS 3 days administration 5 animals_1 mg/kg/day

Control group 2: LPS 3-day administration_1 mg/kg/day + imipramine 30 mg/kg, an existing antidepressant

Example 1 (100): LPS 3-day administration_1 mg/kg/day + 100 mg/kg of the extract of Example 1

Example 1 (300): LPS 3-day administration_1 mg/kg/day + 300 mg/kg of the extract of Example 1

Example 2 (100): LPS 3-day administration_1 mg/kg/day + 100 mg/kg of the extract of Example 2

Example 2 (300): 3-day administration of LPS_1 mg/kg/day + 300 mg/kg of the extract of Example 2

Test Example 1. Immobility time measurement

An antidepressant test on avoidance ability in an emergency situation was conducted from a behavioral pharmacological point of view through a forced swimming test.

To measure the forced swim test (FST), a transparent beaker with a height of 30 cm or more was filled with water (temperature: 23 to 25 ° C.) to a depth of 15 cm, and mice were introduced and forced to swim for 6 minutes. It was obtained and recorded as a digital video file for 6 minutes, and the immobility and swimming time were analyzed using a behavioral analysis program (SMART v3.0, Panlab SL, Barcelona, Spain). For each result, immobility time and swimming time, respectively, in which the mouse stays still without movement on the surface of the water were analyzed for the remaining 4 minutes except for the first 2 minutes.

division Normal group Control 1 Control 2
(IMI) Example 1 (100) Example 1 (300) Example 2 (200) Example 2 (300) floating time
(sec) 129.5 211.5 150.0 149.5 130.5 195.5 190.5 moving time (sec) 110.5 31.5 91.5 90.5 102.0 65.5 75.5

As shown in Table 1 above, it was confirmed that the frozen time was reduced and the moving time was increased compared to the control group 1 in the extracts prepared according to Examples 1 and 2 of the present invention.

In particular, it was confirmed that the frozen time of the leaf extract of Example 1 was reduced and the moving time increased compared to the extract of the rhizome of Example 2.

In addition, Example 1 (100) showed similar values to the control group 2 (imipramine, antidepressant), and Example 1 (300) showed a decrease in immobility time and an increase in movement time compared to the control group 2.

In addition, due to the forced swimming experiment, it was confirmed that the exercise time increased because the still time decreased and the moving time increased in the leaf extract of Example 1. Accordingly, since the extract of the leaf extract of Japanese violet japonica of Example 1 is excellent in improving exercise capacity, it can be used as a food composition for enhancing exercise capacity.

Since the extract of Example 1 is more effective than Example 2, an experiment was carried out with the extract of the leaf extract of Example 1 in the following.

Test Example 2. Passive avoidance test

A passive avoidance system (GEMINI avoidance system, SD instrument, CA, USA) was used to measure the efficacy of the leaf extract of Example 1 on improving cognitive function due to depression. There are 24 cm X 20 cm X 20 cm chambers on both sides with a guillotine door in the middle, and a grid is installed on the bottom of each chamber so that current flows in the dark room. When an experimental animal is placed in the right chamber, the light in the chamber turns on after 10 seconds of adaptation time, and the guillotine door opens at the same time. At this time, due to the instinct to move to the dark part of the mouse, it moves to the dark place, and it is a method of evaluating by measuring the time the mouse enters the dark chamber (step through latency). As soon as the mouse entered the dark room, the guillotine door was closed, and a current of 0.5 mA was passed through the grid on the floor for 2 seconds to give an electric shock to the mouse entering the dark room. When the mouse was taken out and moved to the cage, placed in a bright room again after 24 hours, and the guillotine door was opened, cognitive function was evaluated by measuring the time it took not to enter the black part of the box by remembering the previous day's electric shock.

Figure 1 is a graph showing the results of the manual avoidance experiment of the normal group, control group 1, control group 2 and the extract prepared according to Example 1 of the present invention. 1 is a result of improving the cognitive function of mice, which is reduced according to the administration of 1 mg/kg of LPS at a constant time once a day for 3 days.

As shown in Figure 1, the control group 1, which received LPS, exhibited significantly cognitive impairment-related behavior compared to the normal group, which was not administered LPS.

It was confirmed that the leaf extract of Japanese violet japonica prepared according to Example 1 of the present invention significantly improved cognitive decline due to LPS application compared to the LPS-administered group (control group 1).

This means that the extract of Example 1 is effective in improving, preventing or treating cognitive function.

Test Example 3. Open field test

An open field test was conducted to measure the effect of the leaf extract of Example 1 on improving behavioral disorders and anxiety caused by depression. The mouse was left in an open maze (50 X 50 X 50 cm) and recorded as a digital video file for 5 minutes, and its behavior was compared and analyzed through an analysis program (SMART v3.0, Panlab SL, Barcelona, Spain).

Figure 2 is a diagram showing the behavioral patterns of (A) normal group, (B) control group 1, (C) control group 2, and (D) Example 1 (300) group of the present invention; 3 is (A) the total distance traveled by the normal group, control group 1, control group 2, Example 1 (100) group and Example 1 (300) group, (B) normal group, control group 1, control group 2, Example The time the 1 (100) group and the Example 1 (300) group stayed in the center and (C) the normal group, the control group 1, the control group 2, the Example 1 (100) group, and the Example 1 (300) group preferred the corner This is a graph showing an hour.

As shown in Figure 2, as a result of tracing the movement of the mouse for 5 minutes, it was confirmed that the movement was significantly reduced compared to the normal group in the control group 1, in which depressive-like behavior was induced by LPS, Example 1 (300) It was confirmed that a lot of movement significantly improved anxiety.

In addition, as shown in FIG. 3, it was confirmed that the anxiety symptoms (decreased center retention time and increased corner preference time) increased significantly in control group 1 compared to the normal group. In Example 1 (100) and Example 1 (300), the total moving distance increased compared to Control 1, and compared to Controls 1 and 2, central retention time increased and corner preference time decreased, confirming that anxiety was improved. did

These results are judged to improve the anxiety and depressive behavioral patterns in the LPS-induced depression model of the leaf extract of the present invention Example 1.

Hereinafter, formulation examples of the composition containing the powder of the present invention will be described, but the present invention is not intended to limit them, but only to be specifically described.

Formulation Example 1. Preparation of powder

500 mg of extract powder obtained in Example 1

Lactose 100 mg

Talc 10 mg

A powder is prepared by mixing the above ingredients and filling them in an airtight bag.

Formulation Example 2. Preparation of tablets

300 mg of extract powder obtained in Example 1

Corn Starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above ingredients, tablets are prepared by tableting according to a conventional tablet manufacturing method.

Formulation Example 3. Preparation of capsule formulation

200 mg of extract powder obtained in Example 1

3 mg of crystalline cellulose

Lactose 14.8 mg

Magnesium stearate 0.2 mg

Capsules are prepared by mixing the above ingredients and filling them into gelatin capsules according to a conventional capsule preparation method.

Formulation Example 4. Preparation of Injections

600 mg of extract powder obtained in Example 1

Mannitol 180 mg

Sterile Distilled Water for Injection 2974 mg

Na ₂ HPO _4, 12H ₂ O 26 mg

It is prepared with the above component content per 1 ampoule according to the conventional method for preparing injections.

Formulation Example 5. Preparation of liquid formulation

4 g of extract powder obtained in Example 1

Isomerized sugar 10 g

5 g mannitol

Appropriate amount of purified water

According to the conventional liquid formulation manufacturing method, each component is dissolved in purified water, lemon flavor is added in an appropriate amount, the above components are mixed, and then purified water is added to adjust the total amount to 100g, and then filled into a brown bottle to be sterilized. to prepare a liquid.

Formulation Example 6. Preparation of granules

1,000 mg of extract powder obtained in Example 1

Appropriate amount of vitamin mixture

Vitamin A Acetate 70 μg

Vitamin E 1.0 mg

Vitamin B1 0.13 mg

Vitamin B2 0.15 mg

Vitamin B6 0.5 mg

Vitamin B12 0.2 μg

Vitamin C 10 mg

10 μg of biotin

Nicotinamide 1.7 mg

Folic acid 50 μg

Calcium Pantothenate 0.5 mg

Appropriate amount of mineral mixture

Ferrous sulfate 1.75 mg

Zinc Oxide 0.82 mg

Magnesium Carbonate 25.3 mg

Potassium Phosphate Monobasic 15 mg

Dibasic Calcium Phosphate 55 mg

Potassium citrate 90 mg

Calcium Carbonate 100 mg

Magnesium Chloride 24.8 mg

Although the composition ratio of the above vitamin and mineral mixture was prepared by mixing ingredients suitable for granules in a preferred embodiment, the mixing ratio may be arbitrarily modified, and after mixing the above ingredients according to a conventional granule manufacturing method, It can be prepared and used for preparing a health functional food composition according to a conventional method.

Formulation Example 7. Manufacturing of functional beverages

1,000 mg of extract powder obtained in Example 1

Citric Acid 1,000 mg

100 g of oligosaccharides

2 g plum concentrate

1 g of taurine

Add purified water to total 900 mL

After mixing the above ingredients according to the normal health drink manufacturing method, stirring and heating at 85 ° C. for about 1 hour, the resulting solution is filtered and collected in a sterilized 2 L container, sealed and sterilized, and then refrigerated. It is used for preparing the functional beverage composition of the present invention.

Although the composition ratio is a mixture of ingredients suitable for a relatively favorite beverage in a preferred embodiment, the mixing ratio may be arbitrarily modified according to regional and ethnic preferences such as the class of demand, the country of demand, and the purpose of use.

Formulation Example 8: Preparation of feed composition

0.1 kg of the extract powder of Example 1, 25.5 kg of corn, 15.04 kg of wheat, 8.15 kg of wheat flour, 7.4 kg of rice bran, 18 kg of soybean meal, 1 kg of jade gluten, 14 kg of chicken by-products, 9 kg of animal fat and oil, 0.3 kg of processed salt, third phosphate An animal (dog, pet dog) feed composition was prepared by mixing 0.3 kg of calcium, 1 kg of limestone, 0.01 kg of choline chloride, 0.05 kg of vitamins, 0.05 kg of minerals, and 0.1 kg of a digestive enzyme.

Claims (12)

It contains Erythronium japonicum leaf extract as an active ingredient,
The food composition for improving or preventing depressive symptoms or stress, characterized in that the extract of the leaf extract is extracted with 20 to 80% ethanol aqueous solution. delete delete delete delete The food composition for improving or preventing depressive symptoms or stress according to claim 1, wherein the extraction temperature is 60 to 100 °C and the extraction time is 5 to 15 hours. The food composition for improving or preventing depressive symptoms or stress according to claim 1, wherein the immobility time during forced swimming after ingestion of the composition is 130 to 150 seconds. It contains Erythronium japonicum leaf extract as an active ingredient,
A pharmaceutical composition for the prevention or treatment of depressive symptoms or stress, characterized in that the leaf extract is extracted with 20 to 80% ethanol aqueous solution. delete The pharmaceutical composition for preventing or treating depressive symptoms or stress according to claim 8, wherein the immobility time during forced swimming after ingestion of the composition is 130 to 150 seconds. It contains Erythronium japonicum leaf extract as an active ingredient,
The leaf extract is a feed composition for preventing or improving depressive symptoms or stress, characterized in that extracted with 20 to 80% ethanol aqueous solution. It contains Erythronium japonicum leaf extract as an active ingredient,
The leaf extract is a pharmaceutical composition for preventing or treating depressive symptoms or stress, characterized in that extracted with 20 to 80% ethanol aqueous solution.

Images